Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology

Executive Summary

Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.

You may also be interested in...



BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Gilead To File Filgotinib For RA in 2019, Earlier Than Forecast

Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.

Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans

US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel